Regulation	O
of	O
cytotoxic	O
T	O
lymphocyte	O
antigen	O
4	O
by	O
cyclic	O
AMP	O
.	O


Recent	O
studies	O
indicate	O
that	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
induces	O
cytotoxic	O
T	O
lymphocyte	O
antigen	O
(	O
CTLA	O
)	O
4	O
.	O


CTLA4	O
is	O
expressed	O
in	O
T	O
cells	O
,	O
and	O
is	O
a	O
negative	O
regulator	O
of	O
T	O
cell	O
activation	O
.	O


CTLA4	O
expression	O
is	O
regulated	O
by	O
T	O
cell	O
receptor	O
plus	O
CD28	O
(	O
adaptive	O
immune	O
signaling	O
)	O
at	O
both	O
the	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
level	O
.	O


Here	O
,	O
we	O
examine	O
the	O
pathways	O
by	O
which	O
cAMP	O
regulates	O
CTLA4	O
expression	O
,	O
focusing	O
on	O
transcriptional	O
activation	O
.	O


Elevating	O
intracellular	O
cAMP	O
levels	O
by	O
cell	O
-	O
permeable	O
cAMP	O
analogs	O
,	O
the	O
adenylyl	O
cyclase	O
activator	O
,	O
forskolin	O
,	O
or	O
phosphodiesterase	O
inhibitors	O
increases	O
CTLA4	O
mRNA	O
expression	O
in	O
EL4	O
murine	O
T	O
cells	O
and	O
primary	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
.	O


Activation	O
of	O
protein	O
kinase	O
A	O
(	O
using	O
the	O
protein	O
kinase	O
A	O
-	O
selective	O
agonist	O
,	O
N6	O
-	O
phenyladenosine	O
-	O
cAMP	O
)	O
,	O
but	O
not	O
exchange	O
proteins	O
activated	O
by	O
cAMP	O
(	O
using	O
the	O
exchange	O
proteins	O
activated	O
by	O
cAMP	O
-	O
selective	O
8	O
-	O
pCPT	O
-	O
2Me	O
-	O
cAMP	O
)	O
,	O
increases	O
CTLA4	O
promoter	O
activity	O
.	O


Mutation	O
constructs	O
of	O
the	O
CTLA4	O
promoter	O
uncover	O
an	O
enhancer	B-ENHANCER
binding	I-ENHANCER
site	I-ENHANCER
located	I-ENHANCER
within	I-ENHANCER
the	I-ENHANCER
-	I-ENHANCER
150	I-ENHANCER
to	I-ENHANCER
-	I-ENHANCER
130	I-ENHANCER
bp	I-ENHANCER
region	I-ENHANCER
relative	I-ENHANCER
to	I-ENHANCER
the	I-ENHANCER
transcription	I-ENHANCER
start	I-ENHANCER
site	E-ENHANCER
.	O


Promoter	O
analysis	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
suggest	O
that	O
cAMP	O
response	O
element	O
-	O
binding	O
is	O
a	O
putative	O
transcription	O
factor	O
induced	O
by	O
cAMP	O
.	O


We	O
have	O
previously	O
shown	O
that	O
CTLA4	O
mediates	O
decreased	O
pulmonary	O
inflammation	O
in	O
an	O
LPS	O
-	O
induced	O
murine	O
model	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
.	O


We	O
observed	O
that	O
LPS	O
can	O
induce	O
CTLA4	O
transcription	O
via	O
the	O
same	O
cAMP	O
-	O
inducible	O
promoter	O
region	O
.	O


The	O
immunosuppressant	O
,	O
rapamycin	O
,	O
decreases	O
cAMP	O
and	O
LPS	O
-	O
induced	O
CTLA4	O
transcription	O
in	O
vitro	O
.	O


In	O
vivo	O
,	O
LPS	O
induces	O
cAMP	O
accumulation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
bronchoalveolar	O
lavage	O
cells	O
,	O
and	O
lung	O
tissues	O
in	O
ALI	O
.	O


We	O
demonstrate	O
that	O
rapamycin	O
decreases	O
cAMP	O
accumulation	O
and	O
CTLA4	O
expression	O
in	O
ALI	O
.	O


Together	O
,	O
these	O
data	O
suggest	O
that	O
cAMP	O
may	O
negatively	O
regulate	O
pulmonary	O
inflammatory	O
responses	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
altering	O
CTLA4	O
expression	O
.	O
